What is KYKOY stock price today?

KYKOY (Kyowa Kirin Co., Ltd.) stock is trading at $16.69 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is KYKOY stock going up or down today?

KYKOY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy KYKOY stock now?

The decision to buy KYKOY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is KYKOY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for KYKOY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is KYKOY stock overvalued or undervalued?

KYKOY currently trades at a P/E ratio of 20.86 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if KYKOY is fairly priced.

What is KYKOY's P/E ratio?

KYKOY has a price-to-earnings (P/E) ratio of 20.86, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is KYKOY's market cap?

KYKOY (Kyowa Kirin Co., Ltd.) has a market capitalization of $8.74 billion, making it a small-cap stock.

What is KYKOY's price to book ratio?

KYKOY trades at a price-to-book (P/B) ratio of 1.56, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does KYKOY pay dividends?

Yes, KYKOY pays dividends with a current yield of 0.02%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is KYKOY's dividend yield?

KYKOY's dividend yield is 0.02%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is KYKOY stock a good long-term investment?

KYKOY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is KYKOY's revenue growth rate?

KYKOY has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, KYKOY is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in KYKOY?

Key risks for KYKOY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does KYKOY compare to its competitors?

Compare KYKOY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize KYKOY's performance and positioning.

What is KYKOY's stock price target for 2026?

Our AI model provides price targets for KYKOY based on fundamental analysis: Bull case $21.70 (+30%), Base case $19.19 (+15%), Bear case $15.02 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about KYKOY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for KYKOY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is KYKOY's next earnings report?

KYKOY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

KYKOY - Kyowa Kirin Co., Ltd.

NYSE * Healthcare * Drug Manufacturers - Specialty & Generic

$16.69

+$0.00 (+0.00%)

About Kyowa Kirin Co., Ltd.

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.

KYKOY Key Statistics

Market Cap

$8.74B

P/E Ratio

20.86

P/B Ratio

1.56

EPS

$0.80

Dividend Yield

0.02%

Revenue Growth

+0.1%

Profit Margin

0.1%

Employees

5,161

How KYKOY Compares to Peers

KYKOY ranks 2nd in revenue growth vs peers

KYKOY is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
KYKOY(This stock)	$8.74B	20.9	0%	0.1%	-
LLYEli Lilly	$809.09B	39.3	0%	0.3%	vs LLY
JNJJohnson &	$575.17B	21.8	0%	0.2%	vs JNJ
PFEPfizer Inc	$154.67B	20.0	-0%	0.1%	vs PFE
MRKMerck &	$291.50B	16.2	0%	0.3%	vs MRK
ABBVAbbvie Inc	$368.65B	87.6	0%	0.1%	vs ABBV

Kyowa Kirin Co., Ltd. Company Information

Headquarters: Otemachi Financial City Grand Cube, Chiyoda, Japan, 100-0004, undefined
Website: www.kyowakirin.com
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

About Kyowa Kirin Co., Ltd.

KYKOY Key Statistics

How KYKOY Compares to Peers

Kyowa Kirin Co., Ltd. Company Information

Upcoming Events for KYKOY